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ABSTRACT 
Leukemia is a heterogeneous group of hematological malignancies that originate from the bone 
marrow. Leukemias are classified as acute or chronic. Although acute leukemia affects patients of all 
ages, acute lymphoid leukemia is predominant in children and young adults while acute myeloid 
leukemia (AML) is predominant in the elderly. Combination chemotherapy results in complete 
remission in most of the patients; however, relapse occurs within 1-2 years. After relapse, more 
intensive treatment is usually unsuccessful and associated with high toxicity. Chronic myeloid 
leukemia (CML) is characterized by Bcr/Abl fusion tyrosine kinase that renders CML untreatable with 
conventional chemotherapy. Drugs specifically targeting the Bcr/Abl molecule have been developed, 
but acquired resistance in CML cells jeopardizes treatment success. Therefore, it is important to 
investigate new treatment approaches and strategies. Tetracyclines were discovered during the 1940’s 
as antibiotics. Further development resulted in new analogues, some of them possessing essential non-
antibiotic properties. Tetracycline analogues (TCNAs) were reported to inhibit cell growth in different 
tumor cell lines and cancer models. Their anticancer potency is attributed partially to inhibition of 
matrix metalloproteinases (MMP) and mostly to an apoptosis inducing effect. Cyclophosphamide (Cy) 
is an anticancer drug that is used in the treatment of several cancers including leukemia.  
The aim of the present thesis was to study TCNA-induced cytotoxicity and its underlying mechanisms 
in leukemic cell lines and to assess the mechanisms underlying cyclophosphamide cytotoxicity in vitro 
in the leukemic HL60 cell line.      
The anti-leukemic effects of TCNAs doxycycline (Doxy), minocycline (Mino) and chemically 
modified tetracycline-3 (COL-3) were studied in the human leukemic cell lines AML HL60, 
lymphoblastic Jurkat, AML stem cell like KG1a and CML K562. TCNAs reduced the viability of 
leukemic cells in a concentration-dependent manner with decreasing sensitivity (HL60/Jurkat > K562 
> KG1a). Further studies on molecular mechanisms of TCNAs-induced cell death were performed in 
HL60 and K562 cells. In HL60 cells, all three TCNAs induced apoptosis via mitochondria-mediated 
and caspase-dependent pathways. COL-3 exerted the strongest anti-proliferative and pro-apoptotic 
effect. In K562 cells, doxycycline and minocycline induced cell death that was dependent on caspase 
activity as well as mediated by nuclear DNA damage, increased lysosomal activity, Bcl-xL 
deamidation and activation of mitochondrial apoptotic pathways. However, COL-3 affected K562 
cells by targeting the mitochondria and the nuclear DNA in a concentration-dependent manner. COL-3 
in concentrations above IC50 induced mitochondrial and DNA changes concomitantly, whereas COL-3 
at lower concentrations primarily affected the mitochondria. The COL-3-induced cell death was 
independent of caspase activity, Bcl-xL and intact p53, but mediated by calpain and apoptosis 
inducing factor (AIF). Cy in vitro activation in HL60 cells was catalyzed by CYP2J2 as demonstrated 
by reduction of Cy metabolism and Cy-induced cytotoxicity by telmisartan, a selective inhibitor of 
CYP2J2 enzyme. The role of CYP2J2 in the Cy metabolism was further confirmed by incubation with 
recombinant CYP2J2 enzymes in vitro. Additionally, the CYP2J2 gene is highly expressed in patients 
with hematological malignancies. 
In conclusion: TCNAs possess anti-leukemic activity and induce cell death stimulated by DNA 
damage. The cell death signals are exchanged between nucleus, mitochondria, lysosomes and ER. 
Caspases, calpain and AIF are core machinery for the cell death execution in this model. CYP2J2 is 
involved in bioactivation of Cy in leukemic cells. Studies on combination treatment with Cy and 
TCNAs are warranted. 
 
